New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market

LONDON, June 1, 2015 /PRNewswire/ --

Novel treatments entering the squamous cell carcinoma segment will drive growth, says  GBI Research.

The Non-Small Cell Lung Cancer (NSCLC) treatment market will be driven primarily by the introduction of numerous premium therapies, particularly in second-line and squamous cell treatment settings, which either replace or combine with generic chemotherapies.

Analysis from business intelligence provider GBI Research - Non-Small Cell Lung Cancer Market to 2020 - forecasts the value of the NSCLC treatment market to rise from $5.1 billion in 2013 to over $7.9 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.6%.

For a complimentary sample of this research, please visit the GBI Research website.

NSCLC has an average five-year survival rate of just 14%, making it the largest cause of cancer related death globally. 

There is a large disparity in the survival rates between patients diagnosed with early stage NSCLC and those with advanced disease. However, relatively subtle symptoms and inefficient diagnosis techniques mean that approximately 70% of patients are diagnosed in the later stages of NSCLC.

Analyst Joshua Libberton: "In recent years, new market entrants in the form of targeted therapies and immunotherapies have offered significant improvements to the survival of late-stage NSCLC patients. However, the success of these therapies can often depend on the presence of a particular histological subtype or molecular aberration.

"An active pipeline of almost 400 therapies with considerable diversity in mechanism of action suggests that there will be numerous new products entering the NSCLC treatment space by 2020 that will have a significant impact on disease management and market value."

Key Findings Include:

• Targeted approach remains key as an active and diverse NSCLC treatment pipeline is dominated by therapies targeting growth factors and signal transduction
• Large presence in Phase III of the pipeline will mean numerous new market entrants in the near future, with varying degrees of clinical success and commercial potential
• North America constitutes almost half of the total NSCLC market value, primarily due to high prevalence, high drug prices and the early approval of certain drugs in the US

Click here to find out how this analysis could benefit your business.

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.

For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.

Follow GBI Research online for the latest healthcare industry updates:

Facebook  |LinkedIn  |Twitter

For more information, please contact GBI Research on: [email protected], +44-1204-543-533 or +44-1204-543-537

SOURCE GBI Research